Top 7 Anxiety and Depression Treatment Companies in the World | 2025

The global anxiety and depression treatment market was valued at USD 10.05 billion in 2024. The market is expected to grow at a CAGR of 2.6% during the forecast period of 2025-2034, with the values likely to reach USD 12.67 billion by 2034. The market is driven by the increasing awareness of mental health issues and the rising prevalence of anxiety and depressive disorders globally.

Anxiety and depression are prevalent mental health conditions that significantly impact individuals' well-being and daily functioning. The treatment aims to alleviate symptoms and improve overall mental health. These treatments typically include psychotherapy and pharmacological interventions such as antidepressants and anxiolytics, which target the biological mechanisms underlying these disorders. Lifestyle modifications, including physical exercise, stress management, and mindfulness practices, also help with mental health improvement. In severe cases, advanced treatments like electroconvulsive therapy or transcranial magnetic stimulation are used. A personalized treatment plan ensures effective care for long-term mental well-being.

The global anxiety and depression treatment market has experienced significant growth due to the rising prevalence of anxiety and depressive disorders along with the increasing awareness of mental health issues. Innovative advancements in pharmaceutical treatments, such as the development of new antidepressants and anxiolytics, and psychotherapeutic approaches like cognitive behavioral therapy (CBT), have expanded treatment options. The market is also growing owing to the widespread adoption of telemedicine and digital health platforms, enhancing accessibility to mental health care. With a rising focus on patient-centric solutions, industry players are advancing therapeutic offerings to meet the demand for effective and accessible treatments.

In August 2023, the FDA approved Zurzuvae (zuranolone), the first oral treatment specifically for postpartum depression. Based on positive results from Phase 3 clinical trials, Zurzuvae demonstrated rapid symptom relief within days, providing a new option for women struggling with postpartum depression. This approval represents a breakthrough in mental health treatment, especially in maternal mental health. Such launches are expected to significantly drive growth in the anxiety and depression treatment market, addressing critical unmet needs and offering women timely and effective relief.

Top Companies Leading the Global Anxiety & Depression Market 2025

1.    Pfizer Inc.

Pfizer is a leading global pharmaceutical company dedicated to advancing healthcare through innovative solutions. In the field of anxiety and depression treatment, it offers Pristiq (desvenlafaxine ), a serotonin-norepinephrine reuptake inhibitor that targets major depressive disorder (MDD). It is widely recognized for its efficacy in managing depression, providing clinicians with a reliable option to help patients improve their mental health and quality of life.

2.    GlaxoSmithKline Plc.

GlaxoSmithKline focuses on pharmaceuticals, vaccines, and consumer health products, making them a major healthcare leader. It develops medications aimed at improving mental health in anxiety and depression treatment. With a strong portfolio in central nervous system disorders, including treatments for depression, it continues to expand its offerings to address the growing demand for effective mental health solutions.

3.    AstraZeneca Plc.

AstraZeneca specializes in developing and marketing prescription medicines across multiple therapeutic areas. With a focus on neuroscience, they have been involved in the treatment of various mental health conditions. Their Seroquel SR has been under evaluation for generalized anxiety disorder treatment. They continue to advance their portfolio in psychiatry, aiming to address the growing need for effective treatments for anxiety and depression.

4.    Eli Lily and Co.

Eli Lilly and Company is a healthcare company engaged in the discovery, development, and marketing of human healthcare products. They focus on innovative treatments for anxiety and depression. Their product, Cymbalta/Xeristar (duloxetine hydrochloride), is a dual-reuptake inhibitor targeting serotonin and noradrenaline, designed to address both emotional and physical symptoms of depression. They are dedicated to improving patient outcomes in mental health globally.

5.    Johnson & Johnson Services Inc.

Johnson & Johnson is dedicated to addressing mental health challenges, particularly treatment-resistant depression (TRD). In July 2024, the company submitted a supplemental new drug application (sNDA) to the Food and Drug Administration (FDA) for Spravato (esketamine) as the first monotherapy for adults with treatment-resistant depression. This submission demonstrates the rapid and sustained effectiveness of Spravato in alleviating depressive symptoms, offering hope for patients with unmet needs.

6.    Viatris Inc.

Viatris is committed to improving health outcomes by providing access to a wide range of medicines. Known for its comprehensive portfolio, it focuses on bridging the gap between generics and branded drugs. The company has advanced treatment for generalized anxiety disorder (GAD) with its product Effexor® (venlafaxine). In October 2024, it showed promising results in a Phase 3 study in Japan, offering a new solution for patients with limited treatment options.

7.    Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical is a prominent player in the global anxiety and depression treatment market and offers a range of medications aimed at improving mental health. The company’s Community Routes: Access to Mental Health Care program partners with organizations like the National Association of Free and Charitable Clinics to provide underprivileged populations with access to medicines and behavioral health services. It emphasizes that mental health care extends beyond medication, highlighting the importance of comprehensive support for patients.